These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 11528252

  • 1. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T.
    Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
    [Abstract] [Full Text] [Related]

  • 2. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment.
    Miyajima I, Sata M, Kumashiro R, Uchimura Y, Ide T, Suzuki H, Tanikawa K.
    Oncol Rep; 1998; 5(1):201-4. PubMed ID: 9458322
    [Abstract] [Full Text] [Related]

  • 3. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.
    Int J Cancer; 2000 Sep 01; 87(5):741-9. PubMed ID: 10925370
    [Abstract] [Full Text] [Related]

  • 6. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Hisanaga Y.
    Cancer; 2000 Jan 01; 88(1):58-65. PubMed ID: 10618606
    [Abstract] [Full Text] [Related]

  • 7. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K, Kawano A, Takahashi K, Shigematsu H, Tanaka H, Haruno M, Yanagita K, Ichiki Y, Mori T, Hayashida K, Shimoda S, Ishibashi H, Nomura H.
    Hepatogastroenterology; 2013 Jan 01; 60(128):2034-8. PubMed ID: 24719946
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2007 Jan 01; 50(1):16-23. PubMed ID: 17164553
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May 01; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 11. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
    Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, Hayashi J.
    J Infect Chemother; 2003 Dec 01; 9(4):333-40. PubMed ID: 14691655
    [Abstract] [Full Text] [Related]

  • 12. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K.
    Oncol Rep; 1998 Dec 01; 5(1):205-8. PubMed ID: 9458323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
    Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K.
    World J Gastroenterol; 2007 Oct 28; 13(40):5343-50. PubMed ID: 17879404
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.
    J Gastroenterol Hepatol; 2005 May 28; 20(5):752-8. PubMed ID: 15853990
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.
    J Med Virol; 2007 Oct 28; 79(10):1485-90. PubMed ID: 17705189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.